Digestive Health

Durvalumab continues to demonstrate efficacy in a variety of cancers, with new data from the phase 3 MATTERHORN trial solidifying its use with chemotherapy in gastric cancer.

The study found biosimilar initiation rose to nearly 42% from 2016 to 2023.

A direct link between memories and physical changes has not yet been established.

Clostridioides difficile (C difficile) represents a serious public health threat, with pharmacists and advocacy organizations playing critical roles in prevention, education, and management.

The FDA grants fast track designation to TEV-53408, a promising treatment for celiac disease designed to address gluten intolerance and improve patient outcomes.

Necrotizing enterocolitis (NEC) is a life-threatening illness that is characterized by the inflammation of the intestinal lining, which can lead to intestinal perforation.

Pharmacists can promote prevention through the implementation of antimicrobial stewardship initiatives and advocate for fecal microbiota transplant.

The new indication for guselkumab in Crohn disease builds off a previous approval in ulcerative colitis, providing patients a treatment option for the major forms of inflammatory bowel disease.

The launch of ustekinumab-stba following its FDA approval expands patient access to this therapy with a variety of indications.

Pharmacists can identify medications and conditions that may augment or exacerbate constipation.

The treatment is currently undergoing evaluation in an investigational preclinical program and is projected to be in human trials in 2026.

The designation was granted after positive results from the phase 1 STOMP-I clinical trial (NCT01915927).

New data from the longest known trial of pediatrics and adolescents in the postacute phase of COVID-19 show they are at a heightened risk of gastrointestinal tract symptoms.

The authors are optimistic that these findings may help develop defenses to prevent food allergies in at-risk infants.

The authors are optimistic that this method can be replicated to identify other allergens that manifest into eosinophilic esophagitis (EoE).

BR55, an injection of perfluorobutane/nitrogen lipopeptide-coated microbubbles, could aid in the detection of angiogenesis and allow for earlier diagnosis in patients with Crohn disease.

The decision offers patients with antimicrobial resistance, who have limited or no treatment options, a new alternative.

This is mirikizumab’s second FDA-approved indication in inflammatory bowel disease.

The tablets are indicated for treatment of adults with chronic idiopathic constipation, with further research needed to assess efficacy and safety in children.

The medication, glepaglutide, is in development for the treatment of adults with short bowel syndrome with intestinal failure who are dependent on parenteral support.

Recently announced trial results demonstrate the efficacy of the biologic in multiple disease indications.

The risk of developing lymphoma remained nearly the same between patients with Crohn disease and ulcerative colitis.

Pharmacists will likely be the first contact for many affected patients, and they should be able to provide evidence-based advice on how to manage their infection.

The FDA previously accepted the biologic license application for CT-P13 as a subcutaneous formulation.

Currently, the CDC recommends the recombinant zoster vaccine (Shingrix, RZV; GSK) for the prevention of herpes zoster and related complications.